BioMimetic Augment PMA Delayed Slightly As FDA Seeks Additional Data
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of BioMimetic Therapeutics' Augment synthetic bone graft will likely be delayed by several months after the agency recently requested 12-month follow-up data, the firm said